Overview
Galaxy Biomed
?
Jian Huang
See more contacts
Other Financial Investment Activities
,
Scientific Research and Development Services
,
Electrical Equipment Manufacturing
,
Semiconductor and Other Electronic Component Manufacturing
,
Investors, nec
See All Industries , Biological research , Switchgear and switchboard apparatus Electronic components, nec
See Fewer Industries
See All Industries , Biological research , Switchgear and switchboard apparatus Electronic components, nec
See Fewer Industries
Activities Related to Credit Intermediation
,
Agencies, Brokerages, and Other Insurance Related Activities
,
Depository Credit Intermediation
,
Insurance Carriers
,
Insurance and Employee Benefit Funds
,
Monetary Authorities-Central Bank
,
Nondepository Credit Intermediation
,
Other Investment Pools and Funds
View more , Securities and Commodity Contracts Intermediation and Brokerage Securities and Commodity Exchanges
View fewer
View more , Securities and Commodity Contracts Intermediation and Brokerage Securities and Commodity Exchanges
View fewer
Contacts
Get in Touch with 7 Principals*
-
Jian HuangLegal Representative
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of ? (12 month period) in USD
Annual Revenue 2022
?
USD
Actual
1 USD = 7.2455 CNY
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net Operating Cash | -$5 | -$4 | $6 |
| Net Investing Cash | $1 | $2 | -$3 |
| Net Financing Cash | $3 | -$1 | -$2 |
| Net Change in Cash | -$1 | -$3 | $1 |
| Cash at Beginning of Period | $7 | $10 | $9 |
| Cash at End of Period | $6 | $7 | $10 |
| Capital Expenditure | -$1 | -$3 | -$3 |
| Assets (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $11 | $12 | $15 |
| Accounts Receivable | $93 | $68 | $60 |
| Inventories | $28 | $39 | $32 |
| Other Current Assets | $71 | $37 | $102 |
| Asset Summary | |||
| Total Current Assets | $202 | $155 | $210 |
| Tangible Fixed Assets | $35 | $39 | $38 |
| Intangible Assets | $16 | $16 | $17 |
| Total Assets | $2,007 | $1,726 | $2,131 |
| Liabilities (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $39 | $35 | $42 |
| Short-Term Debt | $25 | $6 | $14 |
| Other Current Liabilities | $79 | $69 | $102 |
| Liability Summary | |||
| Total Current Liabilities | $144 | $110 | $157 |
| Long-Term Debt | $0 | $ | $8 |
| Other Long-Term Liabilities | $298 | $245 | $113 |
| Total Liabilities | $448 | $363 | $285 |
| Stakeholder's Equity (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Equity | |||
| Common Stock | $152 | $152 | $152 |
| Retained Earnings | -$488 | -$439 | -$303 |
| Equity Summary | |||
| Total Equity | -$173 | -$123 | $9 |
| Shares Outstanding | 1,099,911,762 | 1,099,911,762 | 1,099,911,762 |